A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 7/27/2011

Posted by | 11:23pm on Wednesday, July 27, 2011

:
Welcome to tonight’s #socpharm tweetchat, folks! I’m Michael Spitz, VP of Digital Strategy at Ignite Health

:
Please take a moment to introduce yourselves and your interest in healthcare, technology, and/or communications #socpharm

:
Excited to have @: taking the controls for #socpharm tweetchat. I get to sit back & sip my Shiraz when someone says FDA

:
Also please note that all opinions shared will be considered your own, and not necessarily those of any organization #socpharm

:
Don’t be shy, @: is already Shiraz-ing #socpharm

:
Hello everyone! I’m Eileen, work at Siren Interactive, focus on #rarediseases & am all about sharing & learning from each other. #socpharm

:
Hi Michael and Eileen! Angela Dunn, digital pharma analyst interested in learning & sharing trends & tech :) #socpharm

:
Hello, Angela, and welcome aboard #socpharm

:
While folks tune in, let’s consider the most exciting piece of news in a while, the FDA draft guidance for mobile apps #socpharm

:
Hello there #socpharm – I’m Jeremy Franz, Digital Strategy Coordinator @ interested in the latest tech innovations in healthcare

:
Topic 1: What do you think of the FDA draft guidance for mobile apps, and the future of #mhealth? http://1.usa.gov/nX9POY #socpharm

:
How do you think this draft guidance will impact the industry? The cost and availability of apps? Pharma’s role? #socpharm

:
A1: I think it means developers will have to track, report adverse events more #mhealth? http://1.usa.gov/nX9POY #socpharm

:
Here is a POV I penned earlier this week regarding the FDA draft guiance and its potential impact http://bit.ly/mZ0GM3 #socpharm

:
@: How do you think developers will be able to enforce that? Will they partner with the FDA? #socpharm

:
T1: It’s gr8t that FDA have come out w/this guidance to help pharma (& others) utilize this increasingly important channel. #socpharm

:
What about distributors like Apple and Android? Might they partner with the FDA to help police the #mhealth space? #socpharm

:
RT @: : Here is a POV I penned re FDA draft guiance and its potential impact http://bit.ly/mZ0GM3 #socpharm

:
@: But might it not also stifle creativity? And shrink the space? More time and money to get apps approved #socpharm

:
Here’s a link to the FDA mobile app draft guidance > http://1.usa.gov/rdxxRZ #HITsm #socpharm

:
@: from Novo Nordisk here just back from Digital Pharma West. #epharma #socpharm

:
Not sure. I asked during the #fdaapps chat last week. RT @: How will developers enforce that? Partner w/ FDA? #socpharm

:
We know what pharma & medical device have to go through for approvals; will #mhealth suffer similarly in terms of cost and delay? #socpharm

:
@: Hi, Craig! Welcome! We’re discussing the FDA draft guidance for mobile apps #socpharm

:
It will certainly mean that people choosing #mhealth developers will have to be careful they choose knowledgeable ones. #socpharm

:
Do you think this draft guidance for apps will influence draft guidance for social media? #socpharm

:
MT @: : ,,,people choosing #mhealth developers will have to be careful they choose knowledgeable ones. #socpharm

:
@: Yes, think it will shrink the space of #mhealth developers but creativity can still thrive within restrictions. #socpharm

:
{erhaps. & will those who comply earn more customers, cred? RT @: : will #mhealth suffer in cost and delay? #socpharm

:
Perhaps. & will those who comply earn more customers, cred? RT @: : will #mhealth suffer in cost and delay? #socpharm

:
Right now more than 20,000 businesses are involved with #mhealth in some way; like pharma, the space will shrink post-regulation #socpharm

:
Kathy Mackey, Houston, listening in to #s4pm and #socpharm tonight

:
Hi, @: — do you think the FDA regulation of medical apps will be a good thing for patients and doctors? #socpharm

:
@: I agree. Certain developers/agencies will develop expertise & become leaders in #mhealth. #socpharm

:
Hi All – Chuck Strand with Siren joining in. #SocPharm

:
The FDA gudiance covers high risk apps that impact patient outcomes — the press thought that was good for pharma — is it? #socpharm

:
Fellow Houstonite! RT @: : Kathy Mackey, Houston, listening in to #s4pm and #socpharm tonight

:
@: Hi Kathy. What’s #s4pm? #socpharm

:
@: society for participatory medicine. #s4pm #socpharm

:
The barriers to entry have definitely been raised. I think as time goes on a standard will be developed (an API for #mHealth?) #socpharm

:
Aha! Thankx. Do they have a weekly chat at this time too? RT @: : @: society for participatory medicine. #s4pm #socpharm

:
Necessarily so or not? RT @: : barriers to entry have been raised. A standard will be developed (an API for #mHealth?) #socpharm

:
1st time at #s4pm but I did see @ today on #Tedx very nice #socpharm

:
Thanks for tip on #s4pm. What time is it on Wednesdays, 8pm? #socpharm

:
Great TED talk! RT @: : 1st time at #s4pm but I did see @ today on #Tedx very nice #socpharm #s4pm

:
Hi all – Frieda Hernandez from Siren joining #socpharm tweetchat. Interested in all things #raredisease #epatient #mhealth #fdasm #epharma

:
I bet – @ always rocks it. RT @: : 1st time at #s4pm but I did see @ today on #Tedx very nice #socpharm

:
Hi @: — what do you think the FDA guidance of mobile med apps mean for pharma marketers? #socpharm

:
The FDA draft guidance focuses on the high risk apps, leaving “health & wellness” apps off the hook — will pharma be more comfy? #socpharm

:
@: In healthcare regulation is inevitable and meant to protect the public. I think #mhealth will thrive anyway #socpharm

:
RT @: : The FDA draft guidance focuses on the high risk apps, leaving “health & wellness” apps off the hook — will pharma be more comfy? #socpharm

:
I think it raises barrier to our entry which I am not sure is a bad thing on its face. #socpharm

:
Does anyone think Apple or Android will partner w/FDA on apps? I don’t see it happening. #socpharm

:
@: @: If guidance is concerned mostly w/apps affecting clinical outcomes, still lots opp 4 patient ed 4 pharma #socpharm

:
You brought up the idea of a “Bad App” program for docs — do you think that would fly? #socpharm

:
RT @: : The FDA draft guidance focuses on the high risk apps, leaving “health & wellness” apps off the hook — will pharma be more comfy? #socpharm

:
@ Unfortunately, I moderate the pharma marketing & social media #socpharm tweetchat every cadelarge: @: Whats in it for Apple & Android you think? #socpharm

:
RT @: : Here is a POV I penned earlier this week regarding the FDA draft guiance and its potential impact http://bit.ly/mZ0GM3 #socpharm

:
@: More what’s in it for the FDA to help monitor and enforce? #socpharm

:
iTunes has tight standards for their apps already — might they similarly police #mhealth apps? #socpharm

:
NOT 4 #pharma RT @: : T1: It’s gr8t that FDA has come out w/this guidance to help pharma (& others) utilize #mhealth #socpharm

:
For safety? Not sure. RT @: : iTunes=tight standards for apps already — might they similarly police #mhealth apps? #socpharm

:
@: Why is the draft guidance bad for pharma? #socpharm

:
@: Exactly – I’m thinking very little in it for Apple or Android by partnering with FDA on compliance. #socpharm

:
RT @: : Right now more than 20,000 businesses are involved with #mhealth in some way; like pharma, the space will shrink post-regulation #socpharm

:
Good question. Love to hear opinions. RT @: : @: Why is the draft guidance bad for pharma? #socpharm

:
YES RT @: : Hi, @: — do you think FDA regulation of medical apps will be a good thing for patients and doctors? #socpharm

:
Apps that diagnose or dose will likely HAVE to get FDA approval — like the drugs they represent #socpharm

:
The “riskier” #mhealth apps are those that are more similar to the definition of med devices. FDA rightly regulates #socpharm

:
I’d think any help FDA could get (with their already limited resources) on policing health apps would be welcomed. #socpharm

:
RT @: : The “riskier” #mhealth apps are those that are more similar to the definition of med devices. FDA rightly regulates #socpharm

:
Unbranded health & wellness apps, unregulated, will be so common that pharma developing them will be “so what?” #socpharm

:
Hello everyone, joining late but glad to be here. Joyce Ercolino from CSL Behring. Interested in digital, mobile & healthcare. #socpharm

:
@: #mhealth #socpharm Hello Everyone, Andrew Lopez, RN Jersey Nurse, lurking, we did touch on this in #hcsm on Sunday

:
Hi @: & @: — What do you think about the FDA regulating #mhealth apps? #socpharm

:
I could see FDA introducing “Bad Apps” program similar to “Bad Ads” campaign. #socpharm

:
@: Hi Andrew! What was the #hcsm consensus? #socpharm

:
good 4 patientsRT @: FDA gudiance covers high risk apps that impact outcomes-press thought was good 4 #pharma-is it? #socpharm

:
@: Having worked the healthit space I think that if an MD is relying on a device for data.. it should be correct #socpharm

:
@: Its already pharma so what if you ask me. #socpharm

:
How much more do you htink apps will cost after the FDA gets involved? #socpharm

:
How much longer will it take to develop an app if it requires regulatory approval? #socpharm

:
RT @: : @: Having worked the healthit space I think if MD is relying on a device for data.. it should be correct #socpharm

:
Not sure Apple/Android is relevant with FDA. They provide platforms not content – fall back on Pharma if branded/disease specific #socpharm

:
Will pharma be more or less motivated to create apps in a more regulated app environment? #socpharm

:
@: We talked about mobile health applications recently, there are reference program, drug references, lab tests, etc #socpharm

:
@: @ I think #mhealth needs standards & 2 serve its’ audience. Not sure abt “bad apps” label. Subjective. #socpharm

:
@: And there are health applications that will provide diagnostic data, blood sugar readings, lab results. #socpharm

:
@: C’mon you know the answer to that! LESS motivated. #socpharm

:
@: But a lot of this conversation is speculative in terms of what will happen after guidance comes down #socpharm

:
Few mobile apps meet FDA draft suggestions now #socpharm RT: @ Here’s our compilation. bit.ly/hQ1a2L #FDAApps

:
@: Not necessarily, Craig — if pharma knows an app can get approved it will be totally safe, no? #socpharm

:
With more structure there’s less risk, which could increase app development in the conservative pharma industry. #SocPharm

:
RT @: Great TED talk! RT @: : 1st time at #s4pm but I did see @ today on #Tedx very nice #socpharm #s4pm

:
@: Reference apps are like books,provide information,diagnostic applications that people will act on worry me #socpharm

:
@: What is definition of safe? #socpharm

:
@: Right, regulation means less apps, but safer ones — pharma could develop branded apps that dx and dose #socpharm

:
@: iPad apps r the way 2 reaching docs & 4 docs 2 edu patients. Maybe the impact/focus goes from iPhone 2 iPad apps? #socpharm

:
@: I feel mobile apps that provide diagnostic data should be regulated same as a blood sugar machine, and certified #socpharm

:
@: Safe from a regulatory POV, de facto assured post-approval #socpharm

:
Learn from best & worst practices! RT @: : I could see FDA introducing “Bad Apps” program similar to “Bad Ads” campaign. #socpharm

:
@: Great point about tablets — not limited to smartphones, especially as tablets evolve #socpharm #greatpoint

:
Agree RT @: : I feel mobile apps that provide diag data should B regulated same as a blood sugar machine, & certified #socpharm

:
RT @: : Learn from best & worst practices! RT @: : I could see FDA introducing “Bad Apps” program similar to “Bad Ads” campaign. #socpharm

:
@: That’s what’s in the draft guidance — those apps WILL be regulated #socpharm

:
Do you think the FDA even has the bandwidth to monitor and police the #mhealth space? #socpharm

:
Patient RT @: Having worked the healthit space I think that if an MD is relying on a device for data..it should be correct #socpharm

:
Do you think draft guidance for social media will be sped up due to their surprisingly quick move on #mhealth? #socpharm

:
@: You make a point but we are not in the software development business. And I doubt we should be. #socpharm

:
Used to regs-scare others awayRT @: : Will pharma b more or less motivated to create apps in more regulated app envir? #socpharm

:
Hope so, but might not be on top of priority list now? RT @: Will draft guidance be sped up b/c quick moving #mhealth? #socpharm

:
Tablets are the future. #epharma and #EVEO-Docs are downloading iPad apps 5 X more than iPhone apps. Selectivity is the key?? #socpharm

:
@: By “we” do you mean pharma? Pharma doesn’t develop software — but pharma DOES utilize it and apply it #socpharm

:
RT @: : Do you think this draft guidance for apps will influence draft guidance for social media? #socpharm

:
RT @: @: Large & small pharma companies already build apps 4 internal usage guided by FDA cGMP reqs. Its doable #socpharm

:
Excellent question. FDA admitted in article several months ago they were already overwhelmed. I’ll look for link. #socpharm

:
Staffing up… RT @: : Do you think the FDA even has the bandwidth to monitor and police the #mhealth space? #socpharm

:
@: I did mean pharma. Use and application internally, yes, but we are talking of external applications, no? #socpharm

:
@: Where did you find those stats? #socpharm

:
RT @: : @: Yes, think it will shrink the space of #mhealth developers but creativity can still thrive within restrictions. #socpharm

:
RT @: : Tablets are the future. #epharma & #EVEO-Docs are downloading iPad apps 5 X more than iPhone apps. Selectivity is key #socpharm

:
@: We’re talking about potential pharma development of branded apps that dx and dose #socpharm

:
No RT @: : Do u think draft guidance for social media will be sped up due to their surprisingly quick move on #mhealth? #socpharm

:
Unlikely but the earlier guidance is drafted the better .@SpitzStrategy: : re: does FDA have bandwidth to police #mhealth space? #socpharm

:
@ Do you think you’ll be buildsing more or less of them post-guidance? #socpharm

:
@: Yes, but that facilitates the mfr process, different than developing software for customers. #socpharm

:
Agreed RT @: : @: You make a point but we are not in the software develop business. And I doubt we should be. #socpharm

:
@: But pharma contracts out the development of apps, as it does websites, CRM, etc. #socpharm

:
@: I’m not sure app dloads are indicative of future given most apps are not used must after dload as I understand. #socpharm

:
RT @: : The FDA gudiance covers high risk apps that impact patient outcomes — the press thought that was good for pharma — is it? #socpharm

:
Apps are also a potentially viable marketing tool for pharma — especially if branded versions can be approved? #socpharm

:
Agreed RT @: : @: Yes, but that facilitates the mfr process, different than developing software for customers. #socpharm

:
@: That’s so good to hear that FDA is staffing up. Can you share link? #socpharm

:
@: Yes, to facilitate conduct of sales and marketing, not same as helping customers treat patients. #socpharm

:
@: FDA regulated apps will be limited to mostlly physician apps that impact patient outcomes #socpharm

:
RT @ Patient Recruitment and the Danger of Social Media Cheerleading: http://t.co/acD9skL #clinicaltrials #socpharm

:
@: @: Would love to see the link as well (on FDA staffing up). #socpharm

:
@: Good point! I just deleted a bunch of apps last night that I never ended up using. #socpharm

:
@: True but it does not require developing them. They lack network effect vs many that have such already. #socpharm

:
@: But branded tools that help customers treat patients are the most powerful form of messaging, no? #socpharm

:
Right. Important to regulate RT @: : @: FDA regs limited to mostlly physician apps that impact patient outcomes #socpharm

:
@: Yes and those tools need not be in an app that I build and then have to get network effect for. #socpharm

:
Pharma creates tools and resources for physicians to use at the point of care — #mhealth is a brave new world for that #socpharm

:
RT @: : The barriers to entry have definitely been raised. I think as time goes on a standard will be developed (an API for #mHealth?) #socpharm

:
@: Can you explain the difference between a point of care tool that is and isn’t an app? #socpharm

:
@: And how many get used when not embedded in platforms MDs already use? I think not many. #socpharm

:
No. RT @: : @: : Do u think draft guide for social will B sped up due 2 FDA quick move on #mhealth? #socpharm

:
@: Great point about low adoption — but might that increase with FDA approval? #socpharm

:
@: No need. The difference is academic. Who builds and owns it is the point I am making. Network effect is everything. #socpharm

:
Like apps for deciding which med to prescribe? RT @: : Pharma makes tools for point of care . #mhealth new for that #socpharm

:
@: Yes, diagnostic apps, apps that recommend treatment options, and perhaps even assist with dosing #socpharm

:
No, Value of app=usage RT @: : @: Great point about low adoption — but might that increase with FDA approval? #socpharm

:
@: I doubt it when popular apps already entrenched networks that FDA approvals aren’t likely to alter. #socpharm

:
@: So what is on the horizon for pharma in #mhealth? #socpharm

:
RT @: : @: In healthcare regulation is inevitable and meant to protect the public. I think #mhealth will thrive anyway #socpharm

:
@: What other apps than these are MDs using at PoC? #socpharm

:
RT @: : I think it raises barrier to our entry which I am not sure is a bad thing on its face. #socpharm

:
@: @: And apps for adherence? #socpharm

:
Read a while back-no link RT @: : @: That’s so good to hear that FDA is staffing up. Can you share link? #socpharm

:
@: But isn’t one goal of pharma marketing to get into that point of care physicians/patient conversation? #socpharm

:
And what better way to influence treatment decisions than through dx, dosing, and adherence tools? #socpharm

:
Partnet, no -help set standards yes.RT @: : Does anyone think Apple or Android will partner w/FDA on apps? I don’t see #socpharm

:
Interesting idea. For tracking or encouraging adherence? RT @: : @: And apps for adherence? #socpharm

:
@: Don’t know but what should be is relevant ubiquity of info/svcs in apps that customers already use, ….. #socpharm

:
@: …not creation of redundant apps as monuments to brands that customers by and large do not use. … #socpharm

:
#mhealth apps are becoming ubiquitous, like social media — if pharma doesn’t participate they will be left behind #socpharm

:
LOW pharma app use at POC RT @: : #Pharma creates tools for #physicians 2 use at point of care #mhealth brave new world #socpharm

:
@: …There are exceptions but I doubt many. #socpharm

:
@: Interesting, but I’m wondering if FDA approval could lend relevance to branded apps? #socpharm

:
RT @: : @: I’m not sure app dloads are indicative of future given most apps are not used must after dload as I understand. #socpharm

:
@: Given your POV, what do you recommend pharma do within #mhealth, especially post-guidance? #socpharm

:
Near zero…RT @: : @: And how many get used when not embedded in platforms MDs already use? I think not many. #socpharm

:
@: I agree but they dont have 2 b Pharma built? That is my only argument. Do Pharmas still publish their own journals? #socpharm

:
Don’t think so. RT @: : @: Interesting, but I’m wondering if FDA approval could lend relevance to branded apps? #socpharm

:
Or HCPs RT @: : @: …not creation of redundant apps as monuments 2 brands that customers by & large do not use #socpharm

:
@: @: But who else would create an app with brand-specific dx and dosing? #socpharm

:
@: @: Pharma could surely be the ones to fund app creation. #socpharm

:
Agree RT @: : @: @: Pharma could surely be the ones to fund app creation. #socpharm

:
@: Yes, but participation does not require app building. Better to practice app embedding. #socpharm

:
@: Agreed, pharma could still fund the process — and provide clinical data #socpharm

:
@: @: @: pharmacy? #socpharm

:
RT @: : @: Don’t know but what should be is relevant ubiquity of info/svcs in apps that customers already use, ….. #socpharm

:
Apps comparing all brands or innovator only? RT @: : @: @: apps w/ brand-specific dx, dosing? #socpharm

:
@: Yes, but only when uniquely non-redundant. #socpharm

:
Amen!RT @: …not creation of redundant apps as monuments to brands that customers by and large do not use. … #socpharm

:
@: As long as the apps are drug-agnostic for the benefit of the patients #socpharm

:
RT @: : @: Exactly – I’m thinking very little in it for Apple or Android by partnering with FDA on compliance. #socpharm

:
Agree. RT @: : @: Yes, but participation does not require app building. Better to practice app embedding. #socpharm

:
Who would sponsor #mhealth tools with pharma branded information? Payers? Advocacy? #socpharm

:
@: But there are already well adopted apps that contain this dx & dosing information. So why product another? #socpharm

:
@: Agreed. Wouldn’t want 6 different blood pressure apps out there that do the same thing. #socpharm

:
@: Apple has never had to play with others when it comes to this sort of thing. Can’t imagine them doing it now. #socpharm

:
Amen to that. RT @: : Apps that diagnose or dose will likely HAVE to get FDA approval — like the drugs they represent #socpharm

:
@: Ever heard of #ePocrates, #medscape and #Skyscape? #socpharm

:
EHR & ERx corps RT @: : @: @: But who else would create an app with brand-specific dx and dosing? #socpharm

:
RT @: : The “riskier” #mhealth apps are those that are more similar to the definition of med devices. FDA rightly regulates #socpharm

:
RT @: : Amen to that. RT @: : Apps that diagnose or dose will likely HAVE to get FDA approval — like the drugs they represent #socpharm

:
RT @: : I’d think any help FDA could get (with their already limited resources) on policing health apps would be welcomed. #socpharm

:
@: Too late, we already have such redundance just among developer so why should pharma crowd in more? #socpharm

:
.@SpitzStrategy: With so many generics, a pharmacy or payer might be better app developer for dosing & adherence. #socpharm

:
@: @: I don’t think Apple plays very well with others in general :) #socpharm

:
Pharma set dx standards? RT @: : @: @: But who else wld create an app w/ brand-specific dx & dosing? #socpharm

:
@: LOL, true, but are they as comprehensive and useful being entireliy brand-neutral? #socpharm

:
Agree! RT @: : @: Too late, we already have such redundance just among developer so why should pharma crowd in more? #socpharm

:
Good point RT @: : @: With so many generics, an RX or payer might B btr app developer for dosing & adherence. #socpharm

:
This has got to be one of the best of these tweetchats ever! :-) #socpharm

:
@: I would look to an ePocrates to consolidate with funding from multiple pharmas. #socpharm

:
Systems must be #doctor & #patient centered & focused-brand focus creates too much confusion for users #socpharm #pharma

:
@: sorry i am chiming in late tonight on #socpharm

:
@: Interesting idea, a pharma consoritum for #mhealth #socpharm

:
Big thanks to @: for moderating. RT @: : This has got to be one of the best of these tweetchats ever! :-) #socpharm

:
That apps that affect patient outcomes, should be regulated. RT @: : @: Hi What was the #hcsm consensus? #socpharm

:
Interesitng: RT @: : Systems must be doctor & patient centered & focused-brand focus creates too much confusion for users #socpharm

:
@: Who can b more comprehensive than #ePocrates? They were apping b4 we knew what apps were. #socpharm

:
Many thanks to everyone for a robust conversation! And @: for the invite! #socpharm

:
#healthIT standards are being set & embedded in #nhin that is being built now. #pharma needs 2 find way 2 partner not supplant #socpharm

:
@: Well hi there! #socpharm

:
RT @: : @: Who can b more comprehensive than ePocrates? They were apping b4 we knew what apps were. #socpharm

:
It might be 1 of the first 1 topic TweetChats 2! #mhealth #socpharm @: This has got to B 1 of the bes… (cont) http://deck.ly/~e8bQN

:
LOL! RT @: : @: Who can b more comprehensive than #ePocrates? They were apping b4 we knew what apps were. #socpharm

:
RT @: : @: Having worked the healthit space I think that if an MD is relying on a device for data.. it should be correct #socpharm

:
@: #epocrates does that already. That is their business model. #socpharm

:
@: Yes, but I hear they’re struggling. #socpharm

:
I’m going on vacation so #socpharm tweetchat will be on break next week, but back on Aug 10! Look forward to more exciting guest moderators.

:
Great food for thought, folks! @: @: @: @: @: @, et al. #socpharm

:
RT @: : @: Who can b more comprehensive than #ePocrates? They were apping b4 we knew what apps were. #socpharm

:
@: In what way? You do business with them? I see no such signs but I do not see everything. :-) #socpharm

:
@: Thanks. Happy to listen in! #socpharm

:
Funding needs to come from a big fish: RT @: : @: Yes, but I hear they’re struggling. #socpharm

:
@: Thanks for hosting, lots of great ideas, feedback #socpharm

:
Thank you @: for leading a great discussion tonight. I’ll post link to transcript tomorrow. #socpharm

:
Thanks @: and @: and everyone for the great convo! #socpharm

:
Vacation? LOL Enjoy! RT @: : Going on vacation so #socpharm tweetchat will be on brk nxt wk, back on 8.10. #socpharm

:
@: @: Thank you for starting the conversation and stimulating ideas! #socpharm

:
Thx @: @: @ @: @: @: and everyone for a wonderful #socpharm chat!

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

4 Pingbacks/Trackbacks

    28 July 2011 at 11:07pm
    Last night's #socpharm tweetchat ...
  • Eileen O'Brien
  • 29 July 2011 at 12:07am
    RT @EileenOBrien: Last night's ...
  • Kenneth Bennett
  • 29 July 2011 at 12:07am
    MT @EileenOBrien: Last night's ...
  • Michael Spitz
  • 04 August 2011 at 12:08am
    The #SocPharm tweetchat is on ...
  • Eileen O'Brien
Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com